Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pranav Gupta

Showing results (101-110 of 123) with videos related to

Pageof 13
Sort By:
Frontiers in Pharmacology|November 15, 2018
VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC TransportersNing Ji, Yuqi Yang, Chao-Yun Cai, et al.
Molecules (Basel, Switzerland)|December 6, 2019
Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 ExpressionDan Liao, Wei Zhang, Pranav Gupta, et al.
Frontiers in Oncology|May 21, 2019
Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer CellsQingbin Cui, Chao-Yun Cai, Hai-Ling Gao, et al.
Biochemical Pharmacology|February 12, 2020
Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2/ABCB1 inhibitorChao-Yun Cai, Wei Zhang, Jing-Quan Wang, et al.
Oncotarget|April 21, 2017
Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cellsYan Wen, Rui-Qiang Zhao, Yun-Kai Zhang, et al.
Acta Pharmaceutica Sinica. B|April 12, 2019
The epigallocatechin gallate derivative Y<sub>6</sub> reverses drug resistance mediated by the ABCB1 transporter both <i>in vitro</i> and <i>in vivo</i>Yan Wen, Ruiqiang Zhao, Pranav Gupta, et al.
Cancer Letters|January 15, 2018
Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transportersYing-Fang Fan, Wei Zhang, Leli Zeng, et al.
Frontiers in Oncology|November 9, 2020
Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 TransporterHai-Ling Gao, Pranav Gupta, Qingbin Cui, et al.
Molecular Therapy Oncolytics|July 17, 2020
A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT PathwayLiuya Wei, Yang Yang, Pranav Gupta, et al.
Oncotarget|October 31, 2015
A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivoNagaraju Anreddy, Atish Patel, Yun-Kai Zhang, et al.
Pageof 13

Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
Frontiers in Pharmacology|November 15, 2018
VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC TransportersNing Ji, Yuqi Yang, Chao-Yun Cai, et al.
Molecules (Basel, Switzerland)|December 6, 2019
Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 ExpressionDan Liao, Wei Zhang, Pranav Gupta, et al.
Frontiers in Oncology|May 21, 2019
Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer CellsQingbin Cui, Chao-Yun Cai, Hai-Ling Gao, et al.
Biochemical Pharmacology|February 12, 2020
Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2/ABCB1 inhibitorChao-Yun Cai, Wei Zhang, Jing-Quan Wang, et al.
Oncotarget|April 21, 2017
Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cellsYan Wen, Rui-Qiang Zhao, Yun-Kai Zhang, et al.
Acta Pharmaceutica Sinica. B|April 12, 2019
The epigallocatechin gallate derivative Y<sub>6</sub> reverses drug resistance mediated by the ABCB1 transporter both <i>in vitro</i> and <i>in vivo</i>Yan Wen, Ruiqiang Zhao, Pranav Gupta, et al.
Cancer Letters|January 15, 2018
Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transportersYing-Fang Fan, Wei Zhang, Leli Zeng, et al.
Frontiers in Oncology|November 9, 2020
Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 TransporterHai-Ling Gao, Pranav Gupta, Qingbin Cui, et al.
Molecular Therapy Oncolytics|July 17, 2020
A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT PathwayLiuya Wei, Yang Yang, Pranav Gupta, et al.
Oncotarget|October 31, 2015
A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivoNagaraju Anreddy, Atish Patel, Yun-Kai Zhang, et al.
Pageof 13